. Author manuscript; available in PMC: 2015 Nov 1.

Published in final edited form as: Arthritis Rheumatol. 2014 Nov;66(11):3151–3159. doi: 10.1002/art.38788

Table 4.

Adverse events after RTX for disease relapse

	Grade 1	Grade 2	Grade 3	Grade 4	Death	Total
Patients receiving RTX at 6 mos	78	18	5	0	1	102
Patients receiving RTX AEs/pt year at 6 mos	6.4	1.5	0.4	0	0.1	8.4
Patients receiving RTX at end of follow-up	113	34	8	0	1	156
Patients receiving RTX AEs/pt year at end of follow-up	3.4	1.0	0.2	0	0.0	4.7
All other patients at 6 mos	1,404	316	88	11	3	1,822
All other patients AEs/pt year at 6 mos	18.5	4.2	1.2	0.1	0.0	24.1
All other patients at 18 mos	1,809	429	111	12	3	2,364
All other patients AEs/pt year at 18 mos	9.0	2.1	0.6	0.1	0.0	11.8